Wesley H. Self, MD, MPH, is the Senior Vice President for Clinical Research, Principal Investigator for Clinical and Translational Science Award (CTSA), and Director of the Vanderbilt Institute for Clinical and Translational Research (VICTR) at Vanderbilt University Medical Center. In these roles, he leads clinical and translational research efforts for Vanderbilt and several multicenter research networks, with a focus on team science and collaboration. He has published over 260 peer-reviewed manuscripts and received over $350 million in research funding. He is a physician who treats patients in the emergency department setting and researcher who focuses on late-stage clinical trials and effectiveness studies in the fields of severe infection and lung injury.
Dr. Self’s research has advanced the methods of pragmatic clinical trials and observational vaccine effectiveness studies. His work has consistently resulted in important findings for patient care, including in the fields of sepsis resuscitation (NEJM 2023), COVID-19 host response therapies (JAMA 2023, JAMA 2020), respiratory failure (NEJM 2022), intubation techniques (JAMA 2022, NEJM 2019), COVID-19 vaccines (BMJ 2022, JAMA 2021), COVID-19 monoclonal antibody therapies (NEJM 2021), medical management of appendicitis (NEJM 2020), ARDS therapeutics (NEJM 2019), intravenous fluid management (NEJM 2018), influenza vaccine effectiveness (JAMA 2015), and pneumonia epidemiology (NEJM 2015). He is the founder and principal investigator of the CDC-funded Investigating Respiratory Viruses in the Acutely Ill (IVY) Network and the Nashville International Coordinating Center.
Dr. Self graduated from medical school at the University of Virginia (2005), received his clinical training in emergency medicine at Northwestern University (2009), and his research training at Vanderbilt University through an MPH program (2011) and clinical research fellowships (2012). He lives in Nashville, Tennessee with is wife and three children.